{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:21:19Z","timestamp":1777879279247,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Drug Safety"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>Ceftolozane\u2013tazobactam (CT) is a recently approved novel cephalosporin and \u03b2-lactamase inhibitor combination agent with in vitro activity against various Gram-positive and Gram-negative pathogens, including several multidrug-resistant (MDR) Gram-negative organisms. CT is currently approved by the US Food and Drug Administration for the treatment of complicated intrabdominal infection and complicated urinary tract infection at a dose of 1.5\u2009g intravenously every 8\u2009h. This agent is an attractive option for MDR osteomyelitis (OM) treatment, but clinical data is limited to case reports and series. Here we report a series of five patients with MDR OM who were treated with CT. Pathogens involved in these infections were MDR Acinetobacter baumannii (two isolates) and MDR Pseudomonas aeruginosa (four isolates). Two patients were disease free 6\u2009months after therapy was discontinued, one required an additional curative surgical procedure, and two (both on high-dose therapy) developed adverse reactions likely related to CT that necessitated early antibiotic discontinuation.<\/jats:p>","DOI":"10.1177\/2042098619862083","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T03:10:10Z","timestamp":1562555410000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Ceftolozane\u2013tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series"],"prefix":"10.1177","volume":"10","author":[{"given":"Xing","family":"Tan","sequence":"first","affiliation":[{"name":"Infectious Diseases Fellow, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8466-3503","authenticated-orcid":false,"given":"Ryan P.","family":"Moenster","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Specialist \u2013 Infectious Diseases, VA St. Louis Health Care System, 915 North Grand Boulevard, St. Louis, MO 63108, USA"},{"name":"Associate Professor of Pharmacy Practice, St. Louis College of Pharmacy, 4588 Parkview Place, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"key":"bibr1-2042098619862083","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0168-2"},{"key":"bibr2-2042098619862083","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1609"},{"key":"bibr3-2042098619862083","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp150049"},{"key":"bibr4-2042098619862083","unstructured":"Cubist Pharmaceuticals U.S. Zerbaxa (ceftolozane\/tazobactam) package insert. Lexington, MA, 2014. http:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zerbaxa\/zerbaxa_pi.pdf."},{"key":"bibr5-2042098619862083","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix182"},{"key":"bibr6-2042098619862083","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2018.02.013"},{"key":"bibr7-2042098619862083","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1628932"},{"key":"bibr8-2042098619862083","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-217005"},{"key":"bibr9-2042098619862083","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx172"},{"key":"bibr10-2042098619862083","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-223202"},{"key":"bibr11-2042098619862083","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.11.003"},{"key":"bibr12-2042098619862083","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-018-1133-5"},{"key":"bibr13-2042098619862083","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.566"},{"key":"bibr14-2042098619862083","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8010024"},{"key":"bibr15-2042098619862083","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62220-0"},{"key":"bibr16-2042098619862083","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ097"}],"container-title":["Therapeutic Advances in Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2042098619862083","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2042098619862083","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2042098619862083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:39:18Z","timestamp":1777592358000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2042098619862083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":16,"alternative-id":["10.1177\/2042098619862083"],"URL":"https:\/\/doi.org\/10.1177\/2042098619862083","relation":{},"ISSN":["2042-0986","2042-0994"],"issn-type":[{"value":"2042-0986","type":"print"},{"value":"2042-0994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"article-number":"2042098619862083"}}